{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T07:57:25Z","timestamp":1789199845255,"version":"build-2803163510"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,20]]},"DOI":"10.7759\/cureus.79372","type":"journal-article","created":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T17:28:50Z","timestamp":1740072530000},"source":"Crossref","is-referenced-by-count":6,"title":["The Future of Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Cas9 Gene Therapy in Cardiomyopathies: A Review of Its Therapeutic Potential and Emerging Applications"],"prefix":"10.7759","author":[{"given":"Ali","family":"Moradi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sina","family":"Khoshniyat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tochukwu","family":"Nzeako","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Amin","family":"Khazeei Tabari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olawale  O","family":"Olanisa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kutiba","family":"Tabbaa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamza","family":"Alkowati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melika","family":"Askarianfard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daoud","family":"Daoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olu","family":"Oyesanmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelina","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yizhi","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.121.057203","article-title":"Toward CRISPR therapies for cardiomyopathies","volume":"144","author":"Nishiyama T","year":"2021","unstructured":"Nishiyama T, Bassel-Duby R, Olson EN. Toward CRISPR therapies for cardiomyopathies. Circulation. 2021, 144:1525-7. 10.1161\/CIRCULATIONAHA.121.057203","journal-title":"Circulation"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2006.09.014","article-title":"The genetic bases of cardiomyopathies","volume":"48","author":"Richard P","year":"2006","unstructured":"Richard P, Villard E, Charron P, Isnard R. The genetic bases of cardiomyopathies. J Am Coll Cardiol. 2006, 48:79-89. 10.1016\/j.jacc.2006.09.014","journal-title":"J Am Coll Cardiol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.201207033","article-title":"Hypertrophic cardiomyopathy: translating cellular cross talk into therapeutics","volume":"199","author":"Teekakirikul P","year":"2012","unstructured":"Teekakirikul P, Padera RF, Seidman JG, Seidman CE. Hypertrophic cardiomyopathy: translating cellular cross talk into therapeutics. J Cell Biol. 2012, 199:417-21. 10.1083\/jcb.201207033","journal-title":"J Cell Biol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1111\/febs.13110","article-title":"Genome modification by CRISPR\/Cas9","volume":"281","author":"Ma Y","year":"2014","unstructured":"Ma Y, Zhang L, Huang X. Genome modification by CRISPR\/Cas9. FEBS J. 2014, 281:5186-93. 10.1111\/febs.13110","journal-title":"FEBS J"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3390\/biom9120878","article-title":"Hypertrophic cardiomyopathy: an overview of genetics and management","volume":"9","author":"Teekakirikul P","year":"2019","unstructured":"Teekakirikul P, Zhu W, Huang HC, Fung E. Hypertrophic cardiomyopathy: an overview of genetics and management. Biomolecules. 2019, 9:10.3390\/biom9120878","journal-title":"Biomolecules"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1038\/nrmicro2577","article-title":"Evolution and classification of the CRISPR-Cas systems","volume":"9","author":"Makarova KS","year":"2011","unstructured":"Makarova KS, Haft DH, Barrangou R, et al.. Evolution and classification of the CRISPR-Cas systems. Nat Rev Microbiol. 2011, 9:467-77. 10.1038\/nrmicro2577","journal-title":"Nat Rev Microbiol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.11.032","article-title":"The biology of CRISPR-Cas: backward and forward","volume":"172","author":"Hille F","year":"2018","unstructured":"Hille F, Richter H, Wong SP, Bratovi\u010d M, Ressel S, Charpentier E. The biology of CRISPR-Cas: backward and forward. Cell. 2018, 172:1239-59. 10.1016\/j.cell.2017.11.032","journal-title":"Cell"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1038\/nrm3486","article-title":"TALENs: a widely applicable technology for targeted genome editing","volume":"14","author":"Joung JK","year":"2013","unstructured":"Joung JK, Sander JD. TALENs: a widely applicable technology for targeted genome editing. Nat Rev Mol Cell Biol. 2013, 14:49-55. 10.1038\/nrm3486","journal-title":"Nat Rev Mol Cell Biol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1038\/nrg3686","article-title":"A guide to genome engineering with programmable nucleases","volume":"15","author":"Kim H","year":"2014","unstructured":"Kim H, Kim JS. A guide to genome engineering with programmable nucleases. Nat Rev Genet. 2014, 15:321-34. 10.1038\/nrg3686","journal-title":"Nat Rev Genet"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1038\/s41580-019-0131-5","article-title":"The next generation of CRISPR-Cas technologies and applications","volume":"20","author":"Pickar-Oliver A","year":"2019","unstructured":"Pickar-Oliver A, Gersbach CA. The next generation of CRISPR-Cas technologies and applications. Nat Rev Mol Cell Biol. 2019, 20:490-507. 10.1038\/s41580-019-0131-5","journal-title":"Nat Rev Mol Cell Biol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1259\/bjr.20130685","article-title":"DNA DSB repair pathway choice: an orchestrated handover mechanism","volume":"87","author":"Kakarougkas A","year":"2014","unstructured":"Kakarougkas A, Jeggo PA. DNA DSB repair pathway choice: an orchestrated handover mechanism. Br J Radiol. 2014, 87:20130685. 10.1259\/bjr.20130685","journal-title":"Br J Radiol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCGENETICS.108.821314","article-title":"Prevalence of sarcomere protein gene mutations in preadolescent children with hypertrophic cardiomyopathy","volume":"2","author":"Kaski JP","year":"2009","unstructured":"Kaski JP, Syrris P, Esteban MT, et al.. Prevalence of sarcomere protein gene mutations in preadolescent children with hypertrophic cardiomyopathy. Circ Cardiovasc Genet. 2009, 2:436-41. 10.1161\/CIRCGENETICS.108.821314","journal-title":"Circ Cardiovasc Genet"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.110.231670","article-title":"In the thick of it: HCM-causing mutations in myosin binding proteins of the thick filament","volume":"108","author":"Harris SP","year":"2011","unstructured":"Harris SP, Lyons RG, Bezold KL. In the thick of it: HCM-causing mutations in myosin binding proteins of the thick filament. Circ Res. 2011, 108:751-64. 10.1161\/CIRCRESAHA.110.231670","journal-title":"Circ Res"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.yjmcc.2011.01.014","article-title":"Cardiac myosin-binding protein C in hypertrophic cardiomyopathy: mechanisms and therapeutic opportunities","volume":"50","author":"Schlossarek S","year":"2011","unstructured":"Schlossarek S, Mearini G, Carrier L. Cardiac myosin-binding protein C in hypertrophic cardiomyopathy: mechanisms and therapeutic opportunities. J Mol Cell Cardiol. 2011, 50:613-20. 10.1016\/j.yjmcc.2011.01.014","journal-title":"J Mol Cell Cardiol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000066323.15244.54","article-title":"Hypertrophic cardiomyopathy: distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy","volume":"107","author":"Richard P","year":"2003","unstructured":"Richard P, Charron P, Carrier L, et al.. Hypertrophic cardiomyopathy: distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy. Circulation. 2003, 107:2227-32. 10.1161\/01.CIR.0000066323.15244.54","journal-title":"Circulation"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-0004.2003.00151.x","article-title":"Mutation spectrum in a large cohort of unrelated consecutive patients with hypertrophic cardiomyopathy","volume":"64","author":"Erdmann J","year":"2003","unstructured":"Erdmann J, Daehmlow S, Wischke S, et al.. Mutation spectrum in a large cohort of unrelated consecutive patients with hypertrophic cardiomyopathy. Clin Genet. 2003, 64:339-49. 10.1034\/j.1399-0004.2003.00151.x","journal-title":"Clin Genet"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw603","article-title":"Defining the genetic architecture of hypertrophic cardiomyopathy: re-evaluating the role of non-sarcomeric genes","volume":"38","author":"Walsh R","year":"2017","unstructured":"Walsh R, Buchan R, Wilk A, et al.. Defining the genetic architecture of hypertrophic cardiomyopathy: re-evaluating the role of non-sarcomeric genes. Eur Heart J. 2017, 38:3461-8. 10.1093\/eurheartj\/ehw603","journal-title":"Eur Heart J"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2013.04.021","article-title":"Mutation spectrum in a large cohort of unrelated Chinese patients with hypertrophic cardiomyopathy","volume":"112","author":"Liu W","year":"2013","unstructured":"Liu W, Liu W, Hu D, et al.. Mutation spectrum in a large cohort of unrelated Chinese patients with hypertrophic cardiomyopathy. Am J Cardiol. 2013, 112:585-9. 10.1016\/j.amjcard.2013.04.021","journal-title":"Am J Cardiol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1080\/ac.67.1.2146562","article-title":"Spectrum and clinical manifestations of mutations in genes responsible for hypertrophic cardiomyopathy","volume":"67","author":"Curila K","year":"2012","unstructured":"Curila K, Benesova L, Penicka M, et al.. Spectrum and clinical manifestations of mutations in genes responsible for hypertrophic cardiomyopathy. Acta Cardiol. 2012, 67:23-9. 10.1080\/ac.67.1.2146562","journal-title":"Acta Cardiol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1002\/humu.20862","article-title":"Diagnostic yield, interpretation, and clinical utility of mutation screening of sarcomere encoding genes in Danish hypertrophic cardiomyopathy patients and relatives","volume":"30","author":"Andersen PS","year":"2009","unstructured":"Andersen PS, Havndrup O, Hougs L, et al.. Diagnostic yield, interpretation, and clinical utility of mutation screening of sarcomere encoding genes in Danish hypertrophic cardiomyopathy patients and relatives. Hum Mutat. 2009, 30:363-70. 10.1002\/humu.20862","journal-title":"Hum Mutat"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.109.202440","article-title":"Evidence from human myectomy samples that MYBPC3 mutations cause hypertrophic cardiomyopathy through haploinsufficiency","volume":"105","author":"Marston S","year":"2009","unstructured":"Marston S, Copeland O, Jacques A, et al.. Evidence from human myectomy samples that MYBPC3 mutations cause hypertrophic cardiomyopathy through haploinsufficiency. Circ Res. 2009, 105:219-22. 10.1161\/CIRCRESAHA.109.202440","journal-title":"Circ Res"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.108.838672","article-title":"Cardiac myosin-binding protein C mutations and hypertrophic cardiomyopathy: haploinsufficiency, deranged phosphorylation, and cardiomyocyte dysfunction","volume":"119","author":"van Dijk SJ","year":"2009","unstructured":"van Dijk SJ, Dooijes D, dos Remedios C, et al.. Cardiac myosin-binding protein C mutations and hypertrophic cardiomyopathy: haploinsufficiency, deranged phosphorylation, and cardiomyocyte dysfunction. Circulation. 2009, 119:1473-83. 10.1161\/CIRCULATIONAHA.108.838672","journal-title":"Circulation"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddn160","article-title":"Beyond the sarcomere: CSRP3 mutations cause hypertrophic cardiomyopathy","volume":"17","author":"Geier C","year":"2008","unstructured":"Geier C, Gehmlich K, Ehler E, et al.. Beyond the sarcomere: CSRP3 mutations cause hypertrophic cardiomyopathy. Hum Mol Genet. 2008, 17:2753-65. 10.1093\/hmg\/ddn160","journal-title":"Hum Mol Genet"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.4070\/kcj.2021.0154","article-title":"Genetics of Cardiomyopathy: Clinical and Mechanistic Implications for Heart Failure","volume":"51","author":"Kim KH","year":"2021","unstructured":"Kim KH, Pereira NL. Genetics of Cardiomyopathy: Clinical and Mechanistic Implications for Heart Failure. Korean Circ J. 2021, 51:797-836. 10.4070\/kcj.2021.0154","journal-title":"Korean Circ J"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCGENETICS.109.912345","article-title":"Coding sequence rare variants identified in MYBPC3, MYH6, TPM1, TNNC1, and TNNI3 from 312 patients with familial or idiopathic dilated cardiomyopathy","volume":"3","author":"Hershberger RE","year":"2010","unstructured":"Hershberger RE, Norton N, Morales A, Li D, Siegfried JD, Gonzalez-Quintana J. Coding sequence rare variants identified in MYBPC3, MYH6, TPM1, TNNC1, and TNNI3 from 312 patients with familial or idiopathic dilated cardiomyopathy. Circ Cardiovasc Genet. 2010, 3:155-61. 10.1161\/CIRCGENETICS.109.912345","journal-title":"Circ Cardiovasc Genet"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehu301","article-title":"Atlas of the clinical genetics of human dilated cardiomyopathy","volume":"36","author":"Haas J","year":"2015","unstructured":"Haas J, Frese KS, Peil B, et al.. Atlas of the clinical genetics of human dilated cardiomyopathy. Eur Heart J. 2015, 36:1123-35. 10.1093\/eurheartj\/ehu301","journal-title":"Eur Heart J"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.116.309396","article-title":"Dilated cardiomyopathy: genetic determinants and mechanisms","volume":"121","author":"McNally EM","year":"2017","unstructured":"McNally EM, Mestroni L. Dilated cardiomyopathy: genetic determinants and mechanisms. Circ Res. 2017, 121:731-48. 10.1161\/CIRCRESAHA.116.309396","journal-title":"Circ Res"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1038\/nrcardio.2013.105","article-title":"Dilated cardiomyopathy: the complexity of a diverse genetic architecture","volume":"10","author":"Hershberger RE","year":"2013","unstructured":"Hershberger RE, Hedges DJ, Morales A. Dilated cardiomyopathy: the complexity of a diverse genetic architecture. Nat Rev Cardiol. 2013, 10:531-47. 10.1038\/nrcardio.2013.105","journal-title":"Nat Rev Cardiol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2018.03.004","article-title":"Genetic evaluation of cardiomyopathy-a Heart Failure Society of America practice guideline","volume":"24","author":"Hershberger RE","year":"2018","unstructured":"Hershberger RE, Givertz MM, Ho CY, et al.. Genetic evaluation of cardiomyopathy-a Heart Failure Society of America practice guideline. J Card Fail. 2018, 24:281-302. 10.1016\/j.cardfail.2018.03.004","journal-title":"J Card Fail"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1110186","article-title":"Truncations of titin causing dilated cardiomyopathy","volume":"366","author":"Herman DS","year":"2012","unstructured":"Herman DS, Lam L, Taylor MR, et al.. Truncations of titin causing dilated cardiomyopathy. N Engl J Med. 2012, 366:619-28. 10.1056\/NEJMoa1110186","journal-title":"N Engl J Med"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/j.pbiomolbio.2012.08.003","article-title":"Titin-based tension in the cardiac sarcomere: molecular origin and physiological adaptations","volume":"110","author":"Anderson BR","year":"2012","unstructured":"Anderson BR, Granzier HL. Titin-based tension in the cardiac sarcomere: molecular origin and physiological adaptations. Prog Biophys Mol Biol. 2012, 110:204-17. 10.1016\/j.pbiomolbio.2012.08.003","journal-title":"Prog Biophys Mol Biol"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00017.2009","article-title":"Muscle giants: molecular scaffolds in sarcomerogenesis","volume":"89","author":"Kontrogianni-Konstantopoulos A","year":"2009","unstructured":"Kontrogianni-Konstantopoulos A, Ackermann MA, Bowman AL, Yap SV, Bloch RJ. Muscle giants: molecular scaffolds in sarcomerogenesis. Physiol Rev. 2009, 89:1217-67. 10.1152\/physrev.00017.2009","journal-title":"Physiol Rev"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1161\/01.RES.0000115522.52554.86","article-title":"Developmental control of titin isoform expression and passive stiffness in fetal and neonatal myocardium","volume":"94","author":"Lahmers S","year":"2004","unstructured":"Lahmers S, Wu Y, Call DR, Labeit S, Granzier H. Developmental control of titin isoform expression and passive stiffness in fetal and neonatal myocardium. Circ Res. 2004, 94:505-13. 10.1161\/01.RES.0000115522.52554.86","journal-title":"Circ Res"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1097\/FJC.0000000000000007","article-title":"Cardiac titin and heart disease","volume":"63","author":"LeWinter MM","year":"2014","unstructured":"LeWinter MM, Granzier HL. Cardiac titin and heart disease. J Cardiovasc Pharmacol. 2014, 63:207-12. 10.1097\/FJC.0000000000000007","journal-title":"J Cardiovasc Pharmacol"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1097\/HCO.0b013e32832a11c6","article-title":"Lamin A\/C deficiency as a cause of familial dilated cardiomyopathy","volume":"24","author":"Malhotra R","year":"2009","unstructured":"Malhotra R, Mason PK. Lamin A\/C deficiency as a cause of familial dilated cardiomyopathy. Curr Opin Cardiol. 2009, 24:203-8. 10.1097\/HCO.0b013e32832a11c6","journal-title":"Curr Opin Cardiol"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2011.08.078","article-title":"Risk factors for malignant ventricular arrhythmias in lamin a\/c mutation carriers a European cohort study","volume":"59","author":"van Rijsingen IA","year":"2012","unstructured":"van Rijsingen IA, Arbustini E, Elliott PM, et al.. Risk factors for malignant ventricular arrhythmias in lamin a\/c mutation carriers a European cohort study. J Am Coll Cardiol. 2012, 59:493-500. 10.1016\/j.jacc.2011.08.078","journal-title":"J Am Coll Cardiol"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2010.09.084","article-title":"SCN5A mutations associate with arrhythmic dilated cardiomyopathy and commonly localize to the voltage-sensing mechanism","volume":"57","author":"McNair WP","year":"2011","unstructured":"McNair WP, Sinagra G, Taylor MR, et al.. SCN5A mutations associate with arrhythmic dilated cardiomyopathy and commonly localize to the voltage-sensing mechanism. J Am Coll Cardiol. 2011, 57:2160-8. 10.1016\/j.jacc.2010.09.084","journal-title":"J Am Coll Cardiol"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2016.09.927","article-title":"Truncating FLNC mutations are associated with high-risk dilated and arrhythmogenic cardiomyopathies","volume":"68","author":"Ortiz-Genga MF","year":"2016","unstructured":"Ortiz-Genga MF, Cuenca S, Dal Ferro M, et al.. Truncating FLNC mutations are associated with high-risk dilated and arrhythmogenic cardiomyopathies. J Am Coll Cardiol. 2016, 68:2440-51. 10.1016\/j.jacc.2016.09.927","journal-title":"J Am Coll Cardiol"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1253\/jcj.48.515","article-title":"Arrhythmogenic right ventricular dysplasia: a clinical model for the study of chronic ventricular tachycardia","volume":"48","author":"Fontaine G","year":"1984","unstructured":"Fontaine G, Frank R, Tonet JL, Guiraudon G, Cabrol C, Chomette G, Grosgogeat Y. Arrhythmogenic right ventricular dysplasia: a clinical model for the study of chronic ventricular tachycardia. Jpn Circ J. 1984, 48:515-38. 10.1253\/jcj.48.515","journal-title":"Jpn Circ J"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198801213180301","article-title":"Right ventricular cardiomyopathy and sudden death in young people","volume":"318","author":"Thiene G","year":"1988","unstructured":"Thiene G, Nava A, Corrado D, Rossi L, Pennelli N. Right ventricular cardiomyopathy and sudden death in young people. N Engl J Med. 1988, 318:129-33. 10.1056\/NEJM198801213180301","journal-title":"N Engl J Med"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1509267","article-title":"Arrhythmogenic right ventricular cardiomyopathy","volume":"376","author":"Corrado D","year":"2017","unstructured":"Corrado D, Link MS, Calkins H. Arrhythmogenic right ventricular cardiomyopathy. N Engl J Med. 2017, 376:61-72. 10.1056\/NEJMra1509267","journal-title":"N Engl J Med"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1086\/344208","article-title":"Mutation in human desmoplakin domain binding to plakoglobin causes a dominant form of arrhythmogenic right ventricular cardiomyopathy","volume":"71","author":"Rampazzo A","year":"2002","unstructured":"Rampazzo A, Nava A, Malacrida S, et al.. Mutation in human desmoplakin domain binding to plakoglobin causes a dominant form of arrhythmogenic right ventricular cardiomyopathy. Am J Hum Genet. 2002, 71:1200-6. 10.1086\/344208","journal-title":"Am J Hum Genet"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1038\/ng1461","article-title":"Mutations in the desmosomal protein plakophilin-2 are common in arrhythmogenic right ventricular cardiomyopathy","volume":"36","author":"Gerull B","year":"2004","unstructured":"Gerull B, Heuser A, Wichter T, et al.. Mutations in the desmosomal protein plakophilin-2 are common in arrhythmogenic right ventricular cardiomyopathy. Nat Genet. 2004, 36:1162-4. 10.1038\/ng1461","journal-title":"Nat Genet"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1086\/509122","article-title":"Arrhythmogenic right ventricular dysplasia\/cardiomyopathy associated with mutations in the desmosomal gene desmocollin-2","volume":"79","author":"Syrris P","year":"2006","unstructured":"Syrris P, Ward D, Evans A, Asimaki A, Gandjbakhch E, Sen-Chowdhry S, McKenna WJ. Arrhythmogenic right ventricular dysplasia\/cardiomyopathy associated with mutations in the desmosomal gene desmocollin-2. Am J Hum Genet. 2006, 79:978-84. 10.1086\/509122","journal-title":"Am J Hum Genet"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(00)02379-5","article-title":"Identification of a deletion in plakoglobin in arrhythmogenic right ventricular cardiomyopathy with palmoplantar keratoderma and woolly hair (Naxos disease)","volume":"355","author":"McKoy G","year":"2000","unstructured":"McKoy G, Protonotarios N, Crosby A, et al.. Identification of a deletion in plakoglobin in arrhythmogenic right ventricular cardiomyopathy with palmoplantar keratoderma and woolly hair (Naxos disease). Lancet. 2000, 355:2119-2124. 10.1016\/s0140-6736(00)02379-5","journal-title":"Lancet"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.105.583674","article-title":"Mutations in desmoglein-2 gene are associated with arrhythmogenic right ventricular cardiomyopathy","volume":"113","author":"Pilichou K","year":"2006","unstructured":"Pilichou K, Nava A, Basso C, et al.. Mutations in desmoglein-2 gene are associated with arrhythmogenic right ventricular cardiomyopathy. Circulation. 2006, 113:1171-9. 10.1161\/CIRCULATIONAHA.105.583674","journal-title":"Circulation"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2009.11.020","article-title":"Compound and digenic heterozygosity contributes to arrhythmogenic right ventricular cardiomyopathy","volume":"55","author":"Xu T","year":"2010","unstructured":"Xu T, Yang Z, Vatta M, et al.. Compound and digenic heterozygosity contributes to arrhythmogenic right ventricular cardiomyopathy. J Am Coll Cardiol. 2010, 55:587-97. 10.1016\/j.jacc.2009.11.020","journal-title":"J Am Coll Cardiol"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1126\/science.aat5056","article-title":"Oligogenic inheritance of a human heart disease involving a genetic modifier","volume":"364","author":"Gifford CA","year":"2019","unstructured":"Gifford CA, Ranade SS, Samarakoon R, et al.. Oligogenic inheritance of a human heart disease involving a genetic modifier. Science. 2019, 364:865-70. 10.1126\/science.aat5056","journal-title":"Science"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.116.310370","article-title":"Postnatal cardiac gene editing using CRISPR\/Cas9 with AAV9-mediated delivery of short guide RNAs results in mosaic gene disruption","volume":"121","author":"Johansen AK","year":"2017","unstructured":"Johansen AK, Molenaar B, Versteeg D, et al.. Postnatal cardiac gene editing using CRISPR\/Cas9 with AAV9-mediated delivery of short guide RNAs results in mosaic gene disruption. Circ Res. 2017, 121:1168-81. 10.1161\/CIRCRESAHA.116.310370","journal-title":"Circ Res"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.119.315862","article-title":"Cardiomyocyte maturation: new phase in development","volume":"126","author":"Guo Y","year":"2020","unstructured":"Guo Y, Pu WT. Cardiomyocyte maturation: new phase in development. Circ Res. 2020, 126:1086-106. 10.1161\/CIRCRESAHA.119.315862","journal-title":"Circ Res"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.116.310283","article-title":"Analysis of cardiac myocyte maturation using CASAAV, a platform for rapid dissection of cardiac myocyte gene function in vivo","volume":"120","author":"Guo Y","year":"2017","unstructured":"Guo Y, VanDusen NJ, Zhang L, et al.. Analysis of cardiac myocyte maturation using CASAAV, a platform for rapid dissection of cardiac myocyte gene function in vivo. Circ Res. 2017, 120:1874-88. 10.1161\/CIRCRESAHA.116.310283","journal-title":"Circ Res"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-06347-2","article-title":"Hierarchical and stage-specific regulation of murine cardiomyocyte maturation by serum response factor","volume":"9","author":"Guo Y","year":"2018","unstructured":"Guo Y, Jardin BD, Zhou P, et al.. Hierarchical and stage-specific regulation of murine cardiomyocyte maturation by serum response factor. Nat Commun. 2018, 9:3837. 10.1038\/s41467-018-06347-2","journal-title":"Nat Commun"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1038\/nature14269","article-title":"Global genetic analysis in mice unveils central role for cilia in congenital heart disease","volume":"521","author":"Li Y","year":"2015","unstructured":"Li Y, Klena NT, Gabriel GC, et al.. Global genetic analysis in mice unveils central role for cilia in congenital heart disease. Nature. 2015, 521:520-4. 10.1038\/nature14269","journal-title":"Nature"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2016.06.037","article-title":"DNA repair profiling reveals nonrandom outcomes at Cas9-mediated breaks","volume":"63","author":"van Overbeek M","year":"2016","unstructured":"van Overbeek M, Capurso D, Carter MM, et al.. DNA repair profiling reveals nonrandom outcomes at Cas9-mediated breaks. Mol Cell. 2016, 63:633-46. 10.1016\/j.molcel.2016.06.037","journal-title":"Mol Cell"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-24743-z","article-title":"Massively parallel in vivo CRISPR screening identifies RNF20\/40 as epigenetic regulators of cardiomyocyte maturation","volume":"12","author":"VanDusen NJ","year":"2021","unstructured":"VanDusen NJ, Lee JY, Gu W, et al.. Massively parallel in vivo CRISPR screening identifies RNF20\/40 as epigenetic regulators of cardiomyocyte maturation. Nat Commun. 2021, 12:4442. 10.1038\/s41467-021-24743-z","journal-title":"Nat Commun"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.117.311059","article-title":"Hypertrophic cardiomyopathy: genetics, pathogenesis, clinical manifestations, diagnosis, and therapy","volume":"121","author":"Marian AJ","year":"2017","unstructured":"Marian AJ, Braunwald E. Hypertrophic cardiomyopathy: genetics, pathogenesis, clinical manifestations, diagnosis, and therapy. Circ Res. 2017, 121:749-70. 10.1161\/CIRCRESAHA.117.311059","journal-title":"Circ Res"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2012.02.068","article-title":"Genetics of hypertrophic cardiomyopathy after 20 years: clinical perspectives","volume":"60","author":"Maron BJ","year":"2012","unstructured":"Maron BJ, Maron MS, Semsarian C. Genetics of hypertrophic cardiomyopathy after 20 years: clinical perspectives. J Am Coll Cardiol. 2012, 60:705-15. 10.1016\/j.jacc.2012.02.068","journal-title":"J Am Coll Cardiol"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-02176-5","article-title":"Base editing correction of hypertrophic cardiomyopathy in human cardiomyocytes and humanized mice","volume":"29","author":"Chai AC","year":"2023","unstructured":"Chai AC, Cui M, Chemello F, et al.. Base editing correction of hypertrophic cardiomyopathy in human cardiomyocytes and humanized mice. Nat Med. 2023, 29:401-11. 10.1038\/s41591-022-02176-5","journal-title":"Nat Med"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.21037\/cdt.2019.02.01","article-title":"Hypertrophic cardiomyopathy: genetics and clinical perspectives","volume":"9","author":"Wolf CM","year":"2019","unstructured":"Wolf CM. Hypertrophic cardiomyopathy: genetics and clinical perspectives. Cardiovasc Diagn Ther. 2019, 9:S388-415. 10.21037\/cdt.2019.02.01","journal-title":"Cardiovasc Diagn Ther"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-02190-7","article-title":"Efficient in vivo genome editing prevents hypertrophic cardiomyopathy in mice","volume":"29","author":"Reichart D","year":"2023","unstructured":"Reichart D, Newby GA, Wakimoto H, et al.. Efficient in vivo genome editing prevents hypertrophic cardiomyopathy in mice. Nat Med. 2023, 29:412-21. 10.1038\/s41591-022-02190-7","journal-title":"Nat Med"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.01387","article-title":"CRISPR gene therapy: applications, limitations, and implications for the future","volume":"10","author":"Uddin F","year":"2020","unstructured":"Uddin F, Rudin CM, Sen T. CRISPR gene therapy: applications, limitations, and implications for the future. Front Oncol. 2020, 10:1387. 10.3389\/fonc.2020.01387","journal-title":"Front Oncol"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.3390\/genes13061093","article-title":"Exploring the potential of symmetric exon deletion to treat non-ischemic dilated cardiomyopathy by removing frameshift mutations in TTN","volume":"13","author":"Rodriguez-Polo I","year":"2022","unstructured":"Rodriguez-Polo I, Behr R. Exploring the potential of symmetric exon deletion to treat non-ischemic dilated cardiomyopathy by removing frameshift mutations in TTN. Genes (Basel). 2022, 13:1093. 10.3390\/genes13061093","journal-title":"Genes (Basel)"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1080\/07853890601145821","article-title":"Genetics of dilated cardiomyopathy","volume":"39","author":"K\u00e4rkk\u00e4inen S","year":"2007","unstructured":"K\u00e4rkk\u00e4inen S, Peuhkurinen K. Genetics of dilated cardiomyopathy. Ann Med. 2007, 39:91-107. 10.1080\/07853890601145821","journal-title":"Ann Med"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.2414","article-title":"Targeted therapies in genetic dilated and hypertrophic cardiomyopathies: from molecular mechanisms to therapeutic targets. A position paper from the Heart Failure Association (HFA) and the Working Group on Myocardial Function of the European Society of Cardiology (ESC)","volume":"24","author":"de Boer RA","year":"2022","unstructured":"de Boer RA, Heymans S, Backs J, et al.. Targeted therapies in genetic dilated and hypertrophic cardiomyopathies: from molecular mechanisms to therapeutic targets. A position paper from the Heart Failure Association (HFA) and the Working Group on Myocardial Function of the European Society of Cardiology (ESC). Eur J Heart Fail. 2022, 24:406-20. 10.1002\/ejhf.2414","journal-title":"Eur J Heart Fail"},{"key":"ref65","article-title":"Pathogenesis of LMNA-Related Dilated Cardiomyopathy","author":"Virtanen L","year":"2022","unstructured":"Virtanen L. Pathogenesis of LMNA-Related Dilated Cardiomyopathy. University of Turku, Turku, Finland; 2022."},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.1016\/j.mehy.2019.05.013","article-title":"CRISPR\/Cas 9 system for the treatment of dilated cardiomyopathy: a hypothesis related to function of a MAP kinase","volume":"128","author":"Olivaes J","year":"2019","unstructured":"Olivaes J, Bonamino MH, Markoski MM. CRISPR\/Cas 9 system for the treatment of dilated cardiomyopathy: a hypothesis related to function of a MAP kinase. Med Hypotheses. 2019, 128:91-3. 10.1016\/j.mehy.2019.05.013","journal-title":"Med Hypotheses"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.ade1633","article-title":"Precise genomic editing of pathogenic mutations in RBM20 rescues dilated cardiomyopathy","volume":"14","author":"Nishiyama T","year":"2022","unstructured":"Nishiyama T, Zhang Y, Cui M, et al.. Precise genomic editing of pathogenic mutations in RBM20 rescues dilated cardiomyopathy. Sci Transl Med. 2022, 14:eade1633. 10.1126\/scitranslmed.ade1633","journal-title":"Sci Transl Med"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.121.024410","article-title":"Brugada syndrome: different experimental models and the role of human cardiomyocytes from induced pluripotent stem cells","volume":"11","author":"Li Y","year":"2022","unstructured":"Li Y, Lang S, Akin I, Zhou X, El-Battrawy I. Brugada syndrome: different experimental models and the role of human cardiomyocytes from induced pluripotent stem cells. J Am Heart Assoc. 2022, 11:e024410. 10.1161\/JAHA.121.024410","journal-title":"J Am Heart Assoc"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24032109","article-title":"Alterations in calcium handling are a common feature in an arrhythmogenic cardiomyopathy cell model triggered by desmosome genes loss","volume":"24","author":"Vallverd\u00fa-Prats M","year":"2023","unstructured":"Vallverd\u00fa-Prats M, Carreras D, P\u00e9rez GJ, Campuzano O, Brugada R, Alcalde M. Alterations in calcium handling are a common feature in an arrhythmogenic cardiomyopathy cell model triggered by desmosome genes loss. Int J Mol Sci. 2023, 24:2109. 10.3390\/ijms24032109","journal-title":"Int J Mol Sci"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.add4248","article-title":"Desmosomal protein degradation as an underlying cause of arrhythmogenic cardiomyopathy","volume":"15","author":"Tsui H","year":"2023","unstructured":"Tsui H, van Kampen SJ, Han SJ, et al.. Desmosomal protein degradation as an underlying cause of arrhythmogenic cardiomyopathy. Sci Transl Med. 2023, 15:eadd4248. 10.1126\/scitranslmed.add4248","journal-title":"Sci Transl Med"},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.122.061335","article-title":"Genome-wide CRISPR screen identifies an NF2-adherens junction mechanistic dependency for cardiac lineage","volume":"149","author":"Lee CJ","year":"2024","unstructured":"Lee CJ, Autio MI, Zheng W, et al.. Genome-wide CRISPR screen identifies an NF2-adherens junction mechanistic dependency for cardiac lineage. Circulation. 2024, 149:1960-79. 10.1161\/CIRCULATIONAHA.122.061335","journal-title":"Circulation"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/329283-the-future-of-clustered-regularly-interspaced-short-palindromic-repeats-crispr-cas9-gene-therapy-in-cardiomyopathies-a-review-of-its-therapeutic-potential-and-emerging-applications","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T17:28:53Z","timestamp":1740072533000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/329283-the-future-of-clustered-regularly-interspaced-short-palindromic-repeats-crispr-cas9-gene-therapy-in-cardiomyopathies-a-review-of-its-therapeutic-potential-and-emerging-applications"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,20]]},"references-count":71,"URL":"https:\/\/doi.org\/10.7759\/cureus.79372","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2,20]]}}}